Arbutus Biopharma Corporation (ABUS)

2,7500 +0,1100 (+4,17%) Alla chiusura: 04:00PM EDT

Arbutus Biopharma Corporation

701 Veterans Circle
Warminster, PA 18974
United States
267 469 0914
https://www.arbutusbio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 73

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Michael J. McElhaugh	Co-Founder, Interim President, CEO & Director	644,4k	N/D	1975
Dr. Michael J. Sofia Ph.D.	Chief Scientific Officer	656,1k	N/D	1958
Mr. David C. Hastings CPA	CFO & Chief Accounting Officer	647,1k	N/D	1961
Ms. Lisa M. Caperelli	Vice President of Investor Relations	N/D	N/D	N/D
Mr. J. Christopher Naftzger BA, Esq., J.D.	General Counsel, Chief Compliance Officer & Secretary	N/D	N/D	1967
Ms. Shannon Briscoe SPHR	Vice President of Human Resources	N/D	N/D	N/D
Dr. Karen Sims M.D., Ph.D.	Chief Medical Officer	N/D	N/D	1971
Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C.	Corporate Secretary	N/D	N/D	1951

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Governance aziendale

L'ISS Governance QualityScore di Arbutus Biopharma Corporation al 1 aprile 2024 è 6. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 6; diritti degli azionisti: 9; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.